June 17, 2022 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC)

June 17, 2022 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC)

The committee will discuss supplemental new drug applications (sNDAs) 210793-s008 and 207318-s011, efficacy supplement resubmission for NUPLAZID (pimavanserin) tablets, submitted by Acadia Pharmaceuticals Inc., for the proposed treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.